Company / Capital Expenditures
BIOCRYST PHARMACEUTICALS INC Capital Expenditures History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$2.5M
FY2025
5-year range
$1.1M / $2.5M
FY2021-FY2025
Trend
+119.6%
vs FY2024
Sector context
#89 of 194
Health Care
What the data says
At $2M, BIOCRYST PHARMACEUTICALS INC's capital expenditures ranks #89 of 194 in the Health Care sector. Capital Expenditures has fluctuated over the past 10 years, ranging from $328,000 in FY2017 to $5M in FY2016.
Based on SEC 10-K filings.
$2M in FY2025 with a 5-year CAGR of +36.9%.
Improved from $2M to $2M over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- +22.2%
- 5-Year CAGR
- +36.9%
- 10-Year CAGR
- -
Sector benchmark
#89 of 194 in Health CareTop 46% of 194This company $2.5M Sector average $117.5M
▼
-97.9% below sector average
Key checks
Key Insights
- 5-year CAGR of +36.9%, indicating consistent growth.
- In FY2025, capital expenditures increased 119.6% year-over-year.
- Ranks #89 out of 194 companies in the Health Care sector.
- Peak capital expenditures was recorded in FY2016.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $2.5M | +119.6% |
| FY2024 | $1.1M | -48.2% |
| FY2023 | $2.2M | +60.5% |
| FY2022 | $1.4M | -43.4% |
| FY2021 | $2.4M | +364.0% |
| FY2020 | $514.0K | +49.9% |
| FY2019 | $343.0K | -6.3% |
| FY2018 | $366.0K | +11.6% |
| FY2017 | $328.0K | -93.8% |
| FY2016 | $5.3M | +3.0% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026